(MENAFN – Investor Brand Network) Soligenix (NASDAQ: SNGX), a late-stage biopharmaceutical company focused on treatments for rare diseases with unmet medical need, reported extended results from its. ..
Networknewsbreaks Soligenix Inc. (NASDAQ: SNGX) Reports Extended Phase 2A Results For SGX302 Gel In Mild-To-Moderate Psoriasis
RELATED ARTICLES
